April 18th 2024
The FDA has approved alectinib for the adjuvant treatment of patients with ALK-positive non-small cell lung cancer with tumors that are least 4 cm or node positive, as detected by an FDA-approved test.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse
View More
Go To PER in Chicago
May 31, 2024 - June 2, 2024
Register Now!
The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward
View More
Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target
View More
Pathology Implications for CEACAM5 as a Therapeutic Target in Advanced NSCLC
View More
Medical Crossfire®: What Are Effective Strategies for Onco-Nurses to Improve Outcomes in Patients with Small Cell Lung Cancer?
View More
Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
22nd Annual Winter Lung Cancer Conference®
January 31, 2025 - February 2, 2025
Register Now!
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Atezolizumab Appears Effective for Patients with NSCLC with High PD-L1 Expression
October 1st 2020The findings from this global, open-label, randomized trial supported the FDA approval of atezolizumab for patients with non-small cell lung cancer with high PD-L1 expression, regardless of histologic type, in May.
PORT Not Recommended as Standard of Care for Completely Resected Stage IIIAN2 NSCLC
September 26th 2020Post-operative radiotherapy was associated with a nonstatistically significant increase in disease-free survival in patients with completely resected stage IIIAN2 non-small cell lung cancer and therefore cannot be recommended as a standard of care.
Phase 3 EMPOWER-Lung 1 Shows Promise for Cemiplimab-rwlc in Advanced PD-L1+ NSCLC
September 23rd 2020Cemiplimab-rwlc (Libtayo) monotherapy led to a significant improvement in overall survival and progression-free survival in patients with advanced non-small cell lung cancer with PD-L1 expression on at least 50% of their tumor cells.
Capmatinib Shows Antitumor Activity in Advanced NSCLC with a MET exon 14 Skipping Mutation
September 10th 2020Capmatinib (Tabrecta) demonstrated substantial antitumor activity in patients with advanced non-small cell lung cancer with a MET exon 14 skipping mutation, especially in those not treated previously.
FDA Approves Pralsetinib for Treatment of Adults with Metastatic RET Fusion-Positive NSCLC
September 8th 2020The approval was based on results from the phase 1/2 ARROW clinical trial, which demonstrated efficacy for pralsetinib in patients with RET fusion-positive NSCLC with or without prior therapy, and regardless of RET fusion partner or central nervous system involvement.
FDA Grants Priority Review to Tepotinib for the Treatment of NSCLC with METex14 Skipping Mutations
August 26th 2020The new drug application was based on results from the pivotal ongoing, single-arm, phase 2 VISION study evaluating tepotinib monotherapy in patients with advanced NSCLC with METex14 skipping alterations.
FDA Approves Generic Form of Pemetrexed for Non-Squamous NSCLC
August 25th 2020The FDA approved a generic form of pemetrexed for injection as a single-agent in patients with locally advanced or metastatic non-squamous non-small cell lung cancer that has not progressed after 4 cycles of first-line platinum-based chemotherapy.
TRIDENT-1 Trial for Repotrectinib Shows Encouraging Data in Subgroup of Patients with NSCLC
August 20th 2020Early interim data from the registrational phase 2 TRIDENT-1 study of repotrectinib was reported by Turning Point Therapeutics, as well as regulatory feedback from the FDA regarding the TRIDENT-1 trial design.
PLCOm2012 Model May Be More Effective in Screening African Americans for Lung Cancer
August 19th 2020These findings suggest that the current lung cancer screening guidelines undercount African Americans and should therefore be modified to avoid worsening the observed disparities between white and African American ever-smokers in lung cancer outcomes.
Afatinib, Osimertinib Sequence Shows Promise for EGFR-Positive NSLC
August 10th 2020The GioTag study demonstrated that sequential afatinib and osimertinib improved overall survival among patients from the US with epidermal growth factor receptor mutation-positive non-small cell lung cancer and a T790M resistance mutation.
Global Lung Cancer Burden Suggests Need for Tailored Measures
July 31st 2020Researchers suggested that based on their findings, increased efforts are needed to implement intervention strategies tailored to local settings to effectively decrease the global lung cancer burden and reduce health inequality.
FDA Grants Breakthrough Therapy Designation to Osimertinib for Early-Stage EGFR+ NSCLC
July 30th 2020The FDA granted breakthrough therapy designation to osimertinib for the adjuvant treatment of patients with early-stage epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent.
Phase 2 CITYSCAPE Trial Shows Promise for Tiragolumab in NSCLC
July 4th 2020Patients with chemotherapy-naïve, locally advanced, or metastatic non-small cell lung cancer who were treated with tiragolumab plus an anti-PD-L1 agent showed better efficacy versus single-agent checkpoint inhibitor therapy alone.